$2.705
-0.083 (-3.05%)收盘时
SBFM 盈利能力与利润率
Evaluating the bottom line, Sunshine Biopharma Inc maintains a gross margin of 25.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -17.41%, while the net margin is -16.88%. These profitability ratios, combined with a Return on Equity (ROE) of -21.93%, provide a clear picture of how effectively SBFM converts its operational activities into shareholder value.
SBFM 同业对比
In the context of the broader market, SBFM competes directly with industry leaders such as SILO and SXTC. With a market capitalization of $2.09M, it holds a significant position in the sector. When comparing efficiency, SBFM's gross margin of 25.35% stands against SILO's -14.77% and SXTC's 28.74%. Such benchmarking helps identify whether Sunshine Biopharma Inc is trading at a premium or discount relative to its financial performance.
Sunshine Biopharma Inc 财务表现
The company has consistently reported negative net income, with losses reaching -2,143,927 USD in Q4 2025 and -1,564,048 USD in Q2 2026. The gross margin is also declining, currently at 25.35% for Q2 2026, down from 35.60% in Q2 2025.
Financials
相关文章
- Treasury Yields and the Stock Market: What a Near-5% 10-Year Yield Means for Investors in 2026The 10-year Treasury yield hit 5.31% in October 2026 before easing to 4.88%. Learn how Treasury yields affect stocks, which sectors react and how to plan.
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。